Monotreme GLP1


Dr Frank Grutzner, PhD

Professor (ARC fellow), University of Adelaide


One of the world’s most important blood glucose lowering agents for diabetes treatment is exenatide, a GLP1 analogue derived from the saliva of the Gila Monster. Similarly, the glucagon-like peptide 1 (GLP1) hormone present in the venom of echidnas and platypuses is postulated to have a similar effect. It is hoped that further investigation of this key hormone present in two of Australia’s most iconic species will lead to a more effective and safer medicine for Type 2 diabetes patients.

AusHealth Research's Contribution

AusHealth Research launched efforts to establish and fund the first phase of the monotreme GLP1 project, and is now supporting a collaborative research program between the University of Adelaide, Flinders University, Monash University, the Royal Adelaide Hospital, and SAHMRI.